# Ibrutinib in Preventing Acute Leukemia in Patients After Reduced-Intensity Conditioning and Stem Cell Transplant

> **NCT03267186** · PHASE2 · COMPLETED · sponsor: **Andrew Rezvani** · enrollment: 8 (actual)

## Conditions studied

- Acute Biphenotypic Leukemia
- Acute Lymphoblastic Leukemia
- Acute Myeloid Leukemia
- Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- Hematopoietic Cell Transplantation Recipient

## Interventions

- **DRUG:** Ibrutinib
- **OTHER:** Laboratory Biomarker Analysis

## Key facts

- **NCT ID:** NCT03267186
- **Lead sponsor:** Andrew Rezvani
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-09-12
- **Primary completion:** 2021-04-30
- **Final completion:** 2021-04-30
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2023-08-01

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03267186

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03267186, "Ibrutinib in Preventing Acute Leukemia in Patients After Reduced-Intensity Conditioning and Stem Cell Transplant". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03267186. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*